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The goal of this study was to test the hypothesis that renal medullary heme oxygenase (HO) acts as a buﬀer against Ang-II
dependent hypertension. To test this hypothesis, renal medullary HO activity was blocked using QC-13, an imidazole-dioxolane
HO-1 inhibitor, or SnMP, a classical porphyrin based HO inhibitor. HO inhibitors were infused via IRMI catheters throughout the
study starting 3 days prior to implantation of an osmotic minipump which delivered Ang II or saline vehicle. MAP was increased
by Ang II infusion and further increased by IRMI infusion of QC-13 or SnMP. MAP averaged 113±3, 120±7, 141±2, 153±2, and
154±3mmHg in vehicle, vehicle + IRMI QC-13, Ang II, Ang II + IRMIQC-13, and Ang II + IRMI SnMP treatedmice, respectively
(n = 6). Inhibition of renal medullary HO activity with QC-13 in Ang II infusedmice was also associated with a significant increase
in superoxide production as well as significant decreases in antioxidant enzymes catalase and MnSOD. These results demonstrate
that renal inhibition of HO exacerbates Ang II dependent hypertension through a mechanism which is associated with increases
in superoxide production and decreases in antioxidant enzymes.
1. Introduction
Heme oxygenases (HO) are the critical enzymes responsible
for the breakdown of endogenous heme to biliverdin, carbon
monoxide (CO), and free iron. Biliverdin is subsequently
reduced to bilirubin and free iron is sequestered in the cell
via induction of ferritin [1]. The metabolites of HO have a
multitude of actions in the cardiovascular system. Twomajor
isoforms of HO exist, the inducible form, HO-1, and the
constitutively expressed isoform HO-2.
Several studies have demonstrated that systemic induc-
tion of HO-1 can prevent the development of hypertension
in both experimental and genetic models of hypertension [2–
5]. One study has even reported that HO-1 induction for 3
weeks resulted in a chronic 9-month lowering of blood pres-
sure long after the levels of HO-1 had returned to normal [6].
Despite the experimental evidence for the antihypertensive
eﬀect of systemic HO-1 induction, the mechanism by which
HO-1 induction lowers blood pressure is not known. One
reason for the dependence of systemic induction of HO-1 is
the lack of appropriate models which allow for organ or cell-
type specific induction of HO-1.
Given the importance of the kidneys in the long-term
control of blood pressure, renal induction of HO-1 could
play a significant role in the antihypertensive eﬀect of system-
ic HO-1 inducers [7]. Previous studies have demonstrated
an important role for HO enzymes and their metabolites in
the regulation of renal blood flow [8]. Moreover, intrarenal
medullary interstitial (IRMI) infusion of a metalloporphy-
rin-based HO inhibitor, chromium mesoporphyrin (CrMP),
attenuated renal pressure-natriuresis and resulted in the
development of salt-sensitive hypertension [9]. We recently
reported that kidney-specific induction of HO-1 via direct
intrarenal medullary interstitial infusion of cobalt proto-
porphyrin (CoPP) attenuated the development of Ang II-
dependent hypertension in the mouse [10]. The results of
these studies highlight the importance of intrarenal HO in
the regulation of blood pressure.
Traditional HO inhibitors are built upon metallopor-
phyrins which contain central metal atoms and serve as
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competitive inhibitors of HO enzymes [11, 12]. While these
compounds are eﬀective HO inhibitors, they also result in
significant induction of HO-1 in vivo due to the metals that
are utilized [13, 14]. Recently, a new class of imidazole-
dioxolane HO inhibitors was described [15, 16]. These in-
hibitors are molecules which are similar in structure to heme,
the natural HO substrate, but they do not contain metals
and do not induce HO-1 when used in vitro [17]. We have
previously demonstrated that the imidazole-dioxolane HO-
1 inhibitor, QC-13, can eﬀectively inhibit HO activity when
administered in vivo either by intraperitoneal injection or
IRMI infusion [18].
The role of renalmedullaryHO in the regulation of blood
pressure in Ang II-dependent hypertension is not known.
Previous studies have demonstrated that HO-1 is induced in
the rat but not mouse kidney by Ang II [10, 19–22]. The goal
of the present study was to determine the specific role of renal
medullary HO-1 in the development of Ang II-dependent
hypertension in mouse model by IRMI infusion of either
a classical metalloporphyrin-based HO inhibitor, stannous
mesoporphyrin (SnMP), or the imidazole-dioxolane HO-1
inhibitor, QC-13.
2. Methods
2.1. Animals. Experiments were performed on 12- to 16-
week-old male C57BL/6J mice obtained from Jackson Labs
(Bar Harbor, ME). The mice were fed a standard diet con-
taining 0.29% NaCl and were provided water ad libitum. All
animal protocols were approved by the Institutional Animal
Care and Use Committee at the University of Mississippi
Medical Center and performed in accordance with the Guide
for the Care and Use of Laboratory Animals of the National
Institutes of Health. Studies were performed on 16–20-
week old male C57BL/6J mice (Jackson Labs, Bar Harbor,
ME). All studies were performed in accordance with the
approval of the University of Mississippi Medical Center
Institutional Animal Care and Use Committee (IACUC) and
in line with NIH guidelines. All mice underwent unilateral
nephrectomy of the right kidney to remove potential con-
tributions of the noninfused kidney to the blood pressure
response to experimental manipulations. After seven days,
intramedullary interstitial catheters were implanted 1.5–
2mm into the left kidney as previously described [10, 18].
Saline was then infused through the catheter for a period
of 3 days after which the infusion was switched to QC-
13, (2R,4R)-2-[2-(4-chlorophenyl)ethyl]-2-[(1H-imidazol-
1-yl)methyl]-4-methyl-1,3-dioxolane hydrochloride (25 μM,
in saline), or stannous mesoporphyrin (SnMP, 400 μM, in
saline) in some mice (n = 6/group). Infusions were contin-
ued throughout the entire experimental protocol. Two days
after the switch to QC-13 or SnMPmice were implanted with
osmotic minipumps delivering either vehicle (saline) or Ang
II at a rate of 1 μg/kg/min. Five days after implantation of the
osmotic minipumps, carotid artery catheters were implanted
into the mice as previously described [10, 22]. After a 2-day
recovery period, blood pressures were measured in 3-hour
periods over the next 3 days in conscious, freelymovingmice.
Blood pressure data were continuously collected by a Power-
Lab 8/sp polygraph (AD Instruments, Denver, Colorado) and
acquired on a computer running Chart 4 software provided
by the manufacturer. Mice were euthanized after the last
blood pressure recording session and organs harvested.
2.2. Heme Oxygenase Assay. Heme oxygenase assays were
performed on lysates prepared from the renal medulla.
Medullary protein lysates were prepared previously described
[10, 22]. Briefly, tissue was homogenized in 250mM sucrose,
10mM KPO4, 1mM EDTA, and 0.1mM PMSF (pH 7.7)
in the presence of protease inhibitors (2 μg/mL aprotinin,
leupeptin, and pepstatin). The homogenate was then cen-
trifuged at 3,000 g for 15min at 4◦C and the supernatant
was collected. Protein concentration was measured using
a Bio-Rad protein assay with BSA standards. Reactions
were carried out in a 1.2mls containing: 2mM glucose-6-
phosphate, 0.2 unites glucose-6-phosphate dehydrogenase,
0.8mM NADPH, 20 μM hemin, and 0.5mg of lysates as
previously described [23]. The reactions were incubated for 1
hour at 37◦C in the dark. The formed bilirubin was extracted
with chloroform, and the change in optical density (ΔOD) at
464–530 nm was measured using an extinction coeﬃcient of
40mM/cm for bilirubin. HO activity was expressed as pico-
moles of bilirubin formed per hour per milligram of protein.
2.3. Western Blots. Western blots for HO-1 protein were
performed on lysates prepared from the renal medulla as
described above. Samples of 50 μg of protein were boiled in
Laemmli sample buﬀer (Bio-Rad, Hercules, CA) for 5min
and electrophoresed on 7.5% SDS-polyacrylamide gels and
blotted onto nitrocellulose membrane. Membranes were
blocked with Odyssey blocking buﬀer (LI-COR, Lincoln,
NE) for 2 hours at room temperature, then incubated with
the following antibodies: mouse anti-HO-1 monoclonal an-
tibody (StressGen, Vancouver, Canada 1 : 2000), rabbit anti-
HO-2 polyclonal antibody (StressGen), extracellular (EC),
copper-zinc (CuZN), and manganese (Mn) superoxide dis-
mutase (StressGen, Vancouver, Canada, 1 : 1000), and mouse
antimonoclonal antibody (Sigma, St. Louis, MO, 1 : 10,000).
Primary antibodies were used in conjunction with a
mouse or rabbit anti-β-actin antibody (Gentest, 1 : 5,000)
and incubated overnight at 4◦C. The membranes were then
incubated with Alex 680 goat anti-mouse or anti-rabbit IgG
(Molecular Probes) and IRDye 800 goat anti-mouse or anti-
rabbit IgG (Rockland, Gilbertsville, PA) for 1 hour at room
temperature. The membranes were then visualized using
an Odyssey infrared imager (Li-COR, Lincoln, NE) which
allows for the simultaneous detection of two proteins. Den-
sitometry analysis was performed using Odyssey software
(LI-COR, Lincoln, NE). Levels of each specific protein are
expressed as the ratio to β-actin for each sample.
2.4. Measurement of Renal Medullary Superoxide. Superoxide
production in the renal medulla was measured using the
lucigenin technique as previously described [22]. Briefly,
kidneys were removed and separated into renal cortex and
medulla. The medulla was then homogenized (1 : 8 wt/vol)
in RIPA buﬀer (PBS, 1% Nonidet P-40, 0.5% sodium
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Figure 1: Mean arterial blood pressure (a) and cardiac mass index (b) in control, IRMI QC-13, Ang II + IRMI saline, Ang II + IRMI QC-13,
and Ang II + IRMI SnMP-treated mice, n = 6/group. ∗P < 0.05 as compared to value in control mice. †P < 0.05 as compared to Ang
II-treated mice. IRMI, intrarenal medullary interstitial infusion.
deoxycholate, 0.1% SDS, and a protease inhibitor cocktail;
Sigma Chemical). The samples were centrifuged at 12,000 g
for 20min at 4◦C. The supernatant was incubated with
lucigenin at a final concentration of 5 μM and NADPH at
a final concentration of 100 μM. The samples were allowed
to equilibrate for 3min in the dark, and luminescence was
measured every second for 5–15min with a luminometer
(Berthold, Oak Ridge, TN). Luminescence was recorded as
relative light units (RLU) per min. An assay blank with no
homogenate but containing lucigenin was subtracted from
the reading before transformation of the data. The protein
concentration was measured using a Bio-rad protein assay
with BSA standards. The data are expressed as RLU per min
per milligram protein.
2.5. Statistics. Mean values + SE are presented. Signifi-
cant diﬀerences between mean values were determined by
ANOVA followed by a post hoc test (Dunnett’s). A P < 0.05
was considered to be significant.
3. Results
3.1. IRMI Infusion of HO Inhibitors Exacerbates Ang II-
Dependent Hypertension and Increases Cardiac Hypertrophy.
Mean arterial pressure (MAP) averaged 113 ± 3mmHg in
control mice and was slightly higher (120 ± 7mmHg) in
mice which received IRMI infusion of QC-13 alone. MAP
was significantly increased to 141±2mmHg in Ang II-treated
mice which received IRMI infusion of saline (Figure 1(a)).
MAP was significantly augmented in Ang II-treated mice
which received IRMI infusion of either QC-13 or SnMP
and averaged 153 ± 2 and 154 ± 3mmHg in each group,
respectively (Figure 1(a)). Cardiac hypertrophy as indexed by
the ratio of the heart weight to body weight was significantly
increased in mice infused with Ang II as compared to control
and IRMI QC-13-infused mice averaging 5.8 ± 0.3, versus
4.8 ± 0.2, versus 5 ± 0.2mg/g in each group, respectively
(Figure 1(b)). IRMI infusion of QC-13 or SnMP in Ang
II treated mice resulted in further increases in cardiac
hypertrophy as compared to Ang II treated mice alone with
heart weight to body weight ratios averaging 6.4 ± 0.6 and
7.6 ± 0.6mg/g in each group, respectively (Figure 1(b)).
No diﬀerences in body weights were apparent between the
groups with body weights averaging 26±0.7, versus 27±0.7,
versus 25 ± 0.4, versus 25 ± 0.9, versus 25 ± 0.8 grams in
control, QC-13, Ang II, Ang II + QC-13, and Ang II + SnMP-
treated mice, respectively.
3.2. HO Activity and Protein Levels in the Medulla of
Mice Receiving IRMI Infusion of QC-13 and SnMP. The
eﬀectiveness of IRMI infusion of the HO inhibitors, QC-13
and SnMP, to inhibit renal medullary HO was determined
in each of the experimental groups. In agreement with our
previous studies, HO activity was not aﬀected by Ang II
infusion (Figure 2(a)) [10, 22]. However, IRMI infusion of
QC-13 either alone or in combination with Ang II treatment
resulted in a 38% decrease in medullary HO activity as
compared to levels in both control and Ang II-treated mice
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Figure 2: (a) Renal medullary heme oxygenase activity in control, IRMI QC-13, Ang II + IRMI saline, Ang II + IRMI QC-13, and Ang II
+ IRMI SnMP-treated mice, n = 6/group. (b) Representative western blots of HO-1 and HO-2 proteins from the renal medulla of control,
IRMI QC-13, Ang II + vehicle, Ang II + IRMI QC-13, and Ang II + IRMI SnMP-treated mice, n = 3/group. ∗P < 0.05 as compared to value
in control mice.
(Figure 2(a)). Likewise, IRMI infusion of SnMP also resulted
in a similar level of HO inhibition in the renal medulla
(Figure 2(a)). IRMI infusion of QC-13 had no eﬀect on the
levels of HO-1 protein in the medulla when administered
alone or in combination with Ang II (Figure 2(b)). However,
IRMI infusion of SnMP in Ang II-treated mice resulted
in a significant induction of HO-1 in the renal medulla
(Figure 2(b)). In agreement with previous results, Ang II
infusion had no eﬀect on the levels of HO-1 protein in the
renal medulla (Figure 2(b)) [10, 22]. None of the diﬀerent
treatments had any significant eﬀect on the levels of HO-2
protein in the medulla (Figure 2(b)).
3.3. Inhibition of HO Activity Increases Superoxide Production
in the Renal Medulla. We determined the eﬀect of renal HO
inhibition with QC-13 on superoxide production in the renal
medulla of control and Ang II-infused mice. Superoxide
production was significantly increased by more than 2.5
times in the medulla of Ang II-treated mice as compared
to control mice (Figure 3). IRMI infusion of QC-13 alone
resulted in a significant increase in superoxide production in
the medulla as compared to control mice (Figure 3). IRMI
infusion of QC-13 in mice treated with Ang II resulted
in an even greater increase in renal medullary superoxide
production with levels 3.5-fold greater than those observed
in control mice and 35% greater than those observed in Ang
II-treated mice (Figure 3).
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Figure 3: Renal medullary superoxide production in control, IRMI
QC-13, Ang II + IRMI saline, and Ang II + IRMI QC-13-treated
mice, n = 6/group. Renal medullary superoxide production was
measured using the lucigenin technique as described in Section 2.
∗P < 0.05 as compared to value in control mice. †P < 0.05 as
compared to Ang II-treated mice.
3.4. Inhibition of HO Activity and Antioxidant Proteins in
the Renal Medulla. We determined the eﬀect of renal HO
inhibition with QC-13 on the levels of antioxidant proteins
catalase, CuZn, EC, and Mn SOD in control and Ang
II-infused mice. IRMI infusion of QC-13 resulted in a
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Figure 4: Representative western blots of catalase (a), copper-zinc (CuZn) superoxide dismutase (SOD) (b), extracellular (EC) SOD (c), and
manganese (Mn) SOD (d) from the renal medulla of control, IRMI QC-13, Ang II + IRMI saline, and Ang II + IRMI QC-13-treated mice,
n = 6/group. ∗P < 0.05 as compared to value in control mice. †P < 0.05 as compared to Ang II-treated mice.
significant decrease in renal medullary catalase protein which
was equivalent to the decrease observed in Ang II-treated
mice (Figure 4(a)). However, inhibition of HO activity
during Ang II infusion did not result in further decreases
in renal medullary catalase protein levels (Figure 4(a)). No
differences in renal medullary CuZn SOD protein levels
were observed between any of the experimental groups
(Figure 4(b)). Ang II infusion resulted in a significant de-
crease in EC SOD levels as compared to control mice
(Figure 4(c)). Interestingly, IRMI infusion of QC-13 either
alone or in combination with Ang II treatment resulted in a
significant increase in the levels of renal medullary EC SOD
protein (Figure 4(c)). IRMI infusion of QC-13 resulted in
a significant decrease in renal medullary Mn SOD protein
which was equivalent to the decrease observed in Ang II-
treated mice (Figure 4(d)). Inhibition of HO activity during
Ang II infusion did not result in further decreases in renal
medullary Mn SOD protein levels (Figure 4(d)).
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4. Discussion
The present study was designed to determine the importance
of renal medullary HO in the progression of Ang II-
dependent hypertension. Renal medullary HO activity was
inhibited by IRMI infusion of two separate HO inhibitors,
QC-13, an imidazole-dioxolane HO inhibitor or SnMP, a
classical metalloporphyrin-based HO inhibitor. IRMI infu-
sion of either QC-13 or SnMP resulted in significant inhibi-
tion of HO activity and enhancement of Ang II-dependent
hypertension as compared to mice infused with vehicle.
Our present results confirm our previous observations that
infusion of Ang II does not induce either HO-1 protein
or increase HO activity in the mouse kidney [10, 22].
These results are opposite to the eﬀect that Ang II infusion
has on HO protein and activity in the rat kidney where
several studies have demonstrated that Ang II treatment is an
inducer of renal HO-1 [19–21]. The diﬀerences in the renal
response to Ang II between the rat and mouse are not known
and could be due to species diﬀerences in the promoters of
the HO-1 gene or in the renal response to Ang II infusion.
Our finding that inhibition of HO activity in Ang II-
infused mice exacerbates the blood pressure response and
increases cardiac hypertrophy despite the lack of eﬀect of Ang
II on HO activity and protein in the kidney being similar to
that recently described in a model of low Ang II infusion in
the rat [24]. In this study, inhibition of HO activity resulted
in increased renal vascular resistance and decreased renal
blood flow in Ang II-infused rats despite no measureable
changes in HO activity or protein in the kidney with the dose
of Ang II-infused in the study. Similar eﬀects on renal vascu-
lar resistance and blood flow were not observed in control
rats in which HO was blocked. Interestingly, inhibition of
HO activity resulted in a lowering of blood pressure in the
Ang II-infused rats in this study as measured acutely under
anesthesia [24]. While the diﬀerences in blood pressure
responses between the studies could be due to species dif-
ferences or diﬀerences in the way in which blood pressures
were measured, the results from these two studies lend sup-
port for the hypothesis that HO-1 plays an important role in
the stress response of the kidney even in conditions in which
its activity is not significantly increased. One limitation in the
current study is the lack of peripheral measurement of HO
activity in the mice receiving IRMI QC-13 or SnMP. Thus,
it is possible that systemic spillover of the inhibitors could
have contributed to the increase in blood pressure in the
mice receiving IRMI infusions of QC-13 or SnMP. However,
in a previous study by our group, we could not detected
induction of HO-1 in organs such as the liver and heart
following IRMI infusion of CoPP [10].
The eﬀect of renal medullary inhibition of HO in the
present study is consistent with our previous results which
demonstrated that renal-specific induction of HO-1 can
prevent the development of Ang II-dependent hypertension
[10]. They are also in agreement with previous studies in the
rat demonstrating that renal medullary HO inhibition results
in salt-sensitive hypertension [9]. One potential mechanism
for the increase in blood pressure in mice treated with QC-
13 is the eﬀects of HO inhibition on regional renal blood
flow. HO and its metabolites play an important role in the
regulation of renal medullary blood flow which is important
in the pressure-natriuretic response [8, 25, 26]. However, the
eﬀect of HO inhibition on renal hemodynamics in Ang II
hypertensive mice has yet to be examined.
The current results demonstrate that inhibition of renal
medullary HO activity was associated with an increase in su-
peroxide production in the renal medulla. This observation
is consistent with our previous study in which induction of
HO-1 in the renal medulla was associated with a decrease
in superoxide production [10]. Moreover, specific adenovi-
ral overexpression of HO-1 in TALH decreased Ang II-
dependent oxidative damage [27]. The link between HO-1
and its metabolites has also been strengthened in additional
studies from cultured TALH cells which have demonstrated
that increases in HO-1 protein, bilirubin, or CO can at-
tenuate the development of Ang II-dependent superoxide
production [28]. Superoxide anion is a major regulator of
sodium reabsorption in the TALH through direct actions
and through interaction with NO [29–31]. Previous studies
in cultured mouse TALH cells have demonstrated that
blockade of bilirubin formation by inhibition of the con-
version of biliverdin to bilirubin resulted in increased Ang
II-mediated superoxide production and enhancement of
sodium transport [32]. Thus, it is possible that the increase
in renal medullary superoxide production observed after HO
inhibition results in increased sodium reabsorption in the
TALH and enhancement of Ang II hypertension.
Intramedullary interstitial infusion of QC-13 alone
resulted in a significant increase in superoxide production;
yet it only resulted in a slight but not statistically significant
increase in blood pressure. It is not clear why blood pressure
did not increase further in the mice receiving QC-13 alone
but it is possible that in the absence of a physiological stressor
such as Ang II or high salt that increases in superoxide
production are not able to increase blood pressure.
Inhibition of renal medullary HO activity with QC-13
resulted in significant alterations in important antioxidant
enzymes control mice. In agreement with our previous
studies, Ang II infusion also resulted in a significant decrease
in renal medullary catalase levels which was not aﬀected
by blockade of HO-1 with QC-13 [10, 22]. Ang II infusion
also resulted in a significant decrease in renal medullary Mn
SOD levels which again were not altered by intramedullary
inhibition of HO-1 with QC-13. The decrease in renal med-
ullary catalase and Mn SOD observed in the medulla of mice
infused with QC-13 alone suggests an important role for HO
and its metabolites in regulating antioxidant enzymes in the
kidney. Interestingly, inhibition of HO activity with QC-13
resulted in a significant increase in the levels of EC-SOD
which could be a compensatory response to the increase in
superoxide production observed inmice in which QC-13 was
infused.
QC-13 is an imidazole-dioxolane HO inhibitor that has
been reported to selectively inhibit the HO-1 versus HO-
2 isoform [15, 17]. In agreement with our previous in vivo
study, we did not detect any measureable induction of HO-1
in the renal medulla of mice in which QC-13 was adminis-
tered via intrarenal medullary interstitial infusion [18]. This
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was in contrast to infusion of the classic porphyrin-based
HO inhibitor, SnMP, which resulted in significant induction
of HO-1 in the renal medulla. While a diﬀerence in the
induction of HO-1 by these inhibitors was observed, they
both resulted in similar degree of in vitro HO inhibition and
an increase in blood pressure and cardiac hypertrophy in
Ang II-infused mice. However, QC-13 has several technical
advantages over porphyrin-based HO inhibitors like SnMP
including water solubility and light insensitivity which make
its use more appealing for chronic in vivo studies.
In summary, our results demonstrate that inhibition of
renal medullary HO activity exacerbates Ang II-dependent
hypertension and cardiac hypertrophy. The increase in blood
pressure following HO inhibition in Ang II hypertension is
also associated with an increase in renal medullary super-
oxide production and a decrease in antioxidant enzymes in
the renal medulla. These results would suggest that renal
HO-1 plays an important basal role to guard against further
increases in blood pressure in Ang II hypertension through
its antioxidant eﬀects even in states in which it is not induced.
Potential systemic eﬀects of inhibitor spillover could also play
a contribution to the increases in blood pressure. Further
studies are needed to determine the precise roles of vascular
versus tubular eﬀects of HO inhibition as well as to determine
the relative contributions of CO and bilirubin generation.
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